

MEDIMMUNE OFFERS VOLUME-BASED REBATE PROGRAM FOR ETHYOL

The Volume-based Rebate Program for Ethyol will be available to OA Members from July 1, 2006 through December 31, 2006. OA is proud to provide this additional service to our members.



OA Members will automatically receive an **upfront discount of 1%** on all Ethyol purchases with the opportunity to earn an **additional 1% or 2% rebate** (see table below).

REBATES:

At the beginning of each quarter, MedImmune will set volume-based goals for OA Members based on the following criteria:

- > The volume-based goals will be fixed through the Volume-based Rebate Program Term for each quarter. The volume-based goals will be based on each participating member's average quarterly sales volume (in vials) from the previous business quarters plus the appropriate percentage growth pertaining to its office vial size as show in the table below.
- > MedImmune's goal calculation is final and cannot be disputed by OA or the participating member.
- > Rebates will be earned and calculated on a quarterly basis.
- > OA will pay members via check within 90 days of the end of the rebate period.

All OA Members in good standing will be automatically enrolled in this program. Please contact OA at **888-732-7352** with any questions.

	Office Vial Size	Growth Hurdle = Payout	Growth Hurdle 2 = Payout
Tier 1	> 120 vials/	10% growth = 1%	20% growth = 2%
Tier 2	> 60 but <	15% growth = 1%	30% growth = 2%
Tier 3	< 60 vials/qtr	20% growth = 1%	40% growth = 2%

NEW AGREEMENT FOR DACOGEN

Oncology Associates is pleased to announce that Dacogen has been added to the product agreement with MGI PHARMA, INC. The agreement is effective May 22, 2006 and will run until December 31, 2006. In addition to Aloxi, Dacogen is offered to all OA Members in good standing and is available through FloridaInfusion.



Dacogen is indicated for the treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British (FAB) subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System (IPSS) groups.

Visit www.dacogen.com for full prescribing information or call **877-789-DACO (3226)**.

Product Name	Description	NDC #
Aloxi®	0.25 mg/5 ml vial	58063-0797-25
Dacogen™	50 mg vial	58063-0600-50